236 related articles for article (PubMed ID: 11593056)
1. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
[TBL] [Abstract][Full Text] [Related]
2. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
3. Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Arnould S; Guichard S; Hennebelle I; Cassar G; Bugat R; Canal P
Biochem Pharmacol; 2002 Oct; 64(8):1215-26. PubMed ID: 12234602
[TBL] [Abstract][Full Text] [Related]
4. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
5. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
7. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
[TBL] [Abstract][Full Text] [Related]
8. The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Davidson D; Wang Y; Aloyz R; Panasci L
Invest New Drugs; 2013 Apr; 31(2):461-8. PubMed ID: 23054213
[TBL] [Abstract][Full Text] [Related]
9. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.
Arnould S; Hennebelle I; Canal P; Bugat R; Guichard S
Eur J Cancer; 2003 Jan; 39(1):112-9. PubMed ID: 12504667
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells.
Lin YL; Liau JY; Yu SC; Ou DL; Lin LI; Tseng LH; Chang YL; Yeh KH; Cheng AL
PLoS One; 2012; 7(11):e50701. PubMed ID: 23209813
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
12. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
[TBL] [Abstract][Full Text] [Related]
13. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin.
Wei W; Liu Z; Chen X; Bi F
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):702-7. PubMed ID: 24986092
[TBL] [Abstract][Full Text] [Related]
15. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
[TBL] [Abstract][Full Text] [Related]
16. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Park JM; Huang S; Tougeron D; Sinicrope FA
PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
[TBL] [Abstract][Full Text] [Related]
17. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
[TBL] [Abstract][Full Text] [Related]
18. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
Shelton JW; Waxweiler TV; Landry J; Gao H; Xu Y; Wang L; El-Rayes B; Shu HK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):469-76. PubMed ID: 23540347
[TBL] [Abstract][Full Text] [Related]
20. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]